Business Description
AlloVir Inc
NAICS : 541714
SIC : 2834
ISIN : US0198181036
Share Class Description:
ALVR: Ordinary SharesDescription
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.49 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -51.9 | |||||
| 3-Year EPS without NRI Growth Rate | -57.1 | |||||
| 3-Year FCF Growth Rate | -56.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 89.12 | |||||
| 9-Day RSI | 81.75 | |||||
| 14-Day RSI | 73.34 | |||||
| 6-1 Month Momentum % | -72.87 | |||||
| 12-1 Month Momentum % | -78.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.65 | |||||
| Quick Ratio | 6.65 | |||||
| Cash Ratio | 6.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.3 | |||||
| Shareholder Yield % | -3.7 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -77.05 | |||||
| ROA % | -62.73 | |||||
| ROIC % | -427.21 | |||||
| ROC (Joel Greenblatt) % | -647.87 | |||||
| ROCE % | -73.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.27 | |||||
| Price-to-Tangible-Book | 1.27 | |||||
| EV-to-EBIT | -0.49 | |||||
| EV-to-EBITDA | -0.49 | |||||
| EV-to-FCF | -0.7 | |||||
| Price-to-Net-Current-Asset-Value | 1.48 | |||||
| Price-to-Net-Cash | 1.55 | |||||
| Earnings Yield (Greenblatt) % | -204.08 | |||||
| FCF Yield % | -50.39 |
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALVR
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AlloVir Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.68 | ||
| Beta | 0.31 | ||
| Volatility % | 75.66 | ||
| 14-Day RSI | 73.34 | ||
| 14-Day ATR ($) | 0.171317 | ||
| 20-Day SMA ($) | 1.773 | ||
| 12-1 Month Momentum % | -78.45 | ||
| 52-Week Range ($) | 1.31 - 7.31 | ||
| Shares Outstanding (Mil) | 114.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AlloVir Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AlloVir Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
AlloVir Inc Frequently Asked Questions
What is AlloVir Inc(ALVR)'s stock price today?
The current price of ALVR is $2.18. The 52 week high of ALVR is $7.31 and 52 week low is $1.31.
When is next earnings date of AlloVir Inc(ALVR)?
The next earnings date of AlloVir Inc(ALVR) is 2024-02-15 Est..
Does AlloVir Inc(ALVR) pay dividends? If so, how much?
AlloVir Inc(ALVR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers